Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Studio per valutare la sicurezza e l'efficacia dell'AZD2936 nei partecipanti con carcinoma polmonare non a piccole cellule avanzato o metastatico (ARTEMIDE-01)

9 novembre 2026 aggiornato da: AstraZeneca

Studio di fase I/II, in aperto, di incremento della dose e di espansione della dose per valutare la sicurezza, la farmacocinetica, la farmacodinamica e l'efficacia dell'anticorpo AZD2936 anti-TIGIT/anti-PD-1 nei partecipanti con carcinoma polmonare non a piccole cellule avanzato o metastatico

This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer.

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This is a first-time-in-human (FTIH), open-label, multicenter, multi-part, dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics, and efficacy of rilvegostomig (AZD2936) in adult participants with stage III unresectable or stage IV NSCLC. The study includes 4 parts: Part A (dose escalation) and Parts B-E (dose expansion).

Tipo di studio

Interventistico

Iscrizione (Effettivo)

212

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Melbourne, Australia, 3000
        • Research Site
      • Anderlecht, Belgio, 1070
        • Research Site
      • Leuven, Belgio, 3000
        • Research Site
      • Florianópolis, Brasile, 88034-000
        • Research Site
      • Natal, Brasile, 59075-740
        • Research Site
      • Porto Alegre, Brasile, 90035903
        • Research Site
      • Rio de Janeiro, Brasile, 20231-050
        • Research Site
      • São Paulo, Brasile, 01246-000
        • Research Site
      • Chengdu, Cina, 610041
        • Research Site
      • Chongqing, Cina, 400030
        • Research Site
      • Seoul, Corea del Sud, 03722
        • Research Site
      • Seoul, Corea del Sud, 05505
        • Research Site
      • Seoul, Corea del Sud, 03082
        • Research Site
      • Copenhagen, Danimarca, 2100
        • Research Site
      • Dijon, Francia, 21079
        • Research Site
      • Toulouse, Francia, 31059
        • Research Site
      • Tbilisi, Georgia, 0112
        • Research Site
      • Kashiwa, Giappone, 227-8577
        • Research Site
      • Niigata, Giappone, 951-8566
        • Research Site
      • Sendai, Giappone, 981-0914
        • Research Site
      • Tokyo, Giappone, 104-0045
        • Research Site
      • Kuala Lumpur, Malaysia, 59100
        • Research Site
      • Kuching, Malaysia, 93586
        • Research Site
      • Chisinau, Moldavia, MD-2025
        • Research Site
      • Groningen, Olanda, 9713 GZ
        • Research Site
      • Leiden, Olanda, 2333 ZA
        • Research Site
      • Utrecht, Olanda, 3584 CX
        • Research Site
      • Barcelona, Spagna, 08035
        • Research Site
      • Madrid, Spagna, 28041
        • Research Site
      • Madrid, Spagna, 28027
        • Research Site
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60637
        • Research Site
    • Minnesota
      • Rochester, Minnesota, Stati Uniti, 55905
        • Research Site
    • Virginia
      • Fairfax, Virginia, Stati Uniti, 22031
        • Research Site
      • Bangkok, Tailandia, 10700
        • Research Site
      • Chanthaburi, Tailandia, 22000
        • Research Site
      • Muang, Tailandia, 50200
        • Research Site
      • Taichung, Taiwan, 40705
        • Research Site
      • Taichung, Taiwan, 40201
        • Research Site
      • Tainan, Taiwan, 70403
        • Research Site
      • Taipei, Taiwan, 110
        • Research Site

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 130 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Written informed consent
  • Aged 18 or above
  • Part A and Part B: Unresectable stage III or stage IV squamous or non-squamous NSCLC not amenable to curative surgery or radiation. Part C and Part D: Stage IV squamous or non-squamous NSCLC not amenable to curative surgery or radiation. Part E: Stage IV squamous NSCLC not amenable to curative surgery or radiation.
  • Documented PD-L1 expression by PD-L1 IHC per local report.
  • Part A and Part B: Confirmed progression during treatment with a CPI-including regimen.
  • Part C and Part D: No prior I/O treatment for metastatic NSCLC.
  • Part E: No prior treatment for metastatic NSCLC.
  • ECOG performance status of 0 or 1 at enrolment.
  • Life expectancy of ≥ 12 weeks at enrolment.
  • Have at least 1 measurable lesion per RECIST v1.1.
  • Adequate bone marrow, liver and kidney function

Exclusion Criteria:

  • Sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) fusion
  • Documented test result for any other known genomic alteration for which a targeted therapy is approved in first line per local standard of care (e.g. ROS1, NTRK fusions, BRAF, V600E mutation)
  • Previous treatment with an anti-TIGIT therapy
  • Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment.
  • Part A and Part B: Primary or secondary resistance after treatment with 2 or more regiments including a CPI.
  • Part C and Part D: Any prior systemic treatment with an immune oncology agent (prior administration of immune-oncology agent for curative intent to treat other invasive malignancy is permitted).

Treatment with one previous systemic chemotherapy will be allowed.

  • Part E: Any prior systemic treatment for metastatic NSCLC, including but not limited to chemotherapy, anti-PD-1, anti-PD-L1, anti-CTLA-4.
  • Symptomatic central nervous system (CNS) metastasis.
  • Thromboembolic event within 3 months prior to enrolment.
  • Other invasive malignancy within 2 years prior to screening.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Dose Escalation Part A: Checkpoint inhibitor (CPI) experienced Non-small Cell Lung Cancer (NSCLC)

Rilvegostomig Intravenous (IV) monotherapy

Anti-TIGIT/Anti-PD-1 Bispecific Antibody

Altri nomi:
  • Rilvegostomig
Sperimentale: Dose Expansion Part B: CPI experienced NSCLC

Rilvegostomig IV monotherapy

Anti-TIGIT/Anti-PD-1 Bispecific Antibody

Altri nomi:
  • Rilvegostomig
Sperimentale: Dose Expansion Part C: CPI Naive NSCLC

Rilvegostomig IV monotherapy

Anti-TIGIT/Anti-PD-1 Bispecific Antibody

Altri nomi:
  • Rilvegostomig
Sperimentale: Dose Expansion Part D: CPI Naive NSCLC

Rilvegostomig IV monotherapy

Anti-TIGIT/Anti-PD-1 Bispecific Antibody

Altri nomi:
  • Rilvegostomig
Sperimentale: Dose Expansion Part E: treatment Naive Squamous NSCLC

Rilvegostomig IV monotherapy

Anti-TIGIT/Anti-PD-1 Bispecific Antibody

Altri nomi:
  • Rilvegostomig

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of participants with adverse events (AEs) and immune mediated AEs (imAEs), serious AEs (SAEs), dose limiting toxicities (DLTs), vital signs, and abnormal laboratory parameters
Lasso di tempo: Part A, B, C, D and E: From the time of informed consent until 90 days after the last dose of rilvegostomig

A DLT is a toxicity defined by the study protocol that occurs from the first dose of study intervention up to the end of the DLT evaluation period that is assessed as clearly unrelated to the primary disease or intercurrent illness.

Part A, B, C, D and E: From the time of informed consent until 90 days after the last dose of rilvegostomig
Rate of rilvegostomig discontinuation due to toxicity
Lasso di tempo: Part A, B, C, D and E: From first dose to the last dose of rilvegostomig (an average of 6 months)

Percentage of participants with AEs leading to discontinuation of rilvegostomig

Part A, B, C, D and E: From first dose to the last dose of rilvegostomig (an average of 6 months)
Objective Response Rate (ORR)
Lasso di tempo: Part B, C, D and E: From first dose of rilvegostomig to progressive disease (PD) or death in the absence of disease progression (approximately 2 years)

Percentage of participants with a confirmed Complete Response (CR) or Partial Response (PR) according to RECIST v1.1

Part B, C, D and E: From first dose of rilvegostomig to progressive disease (PD) or death in the absence of disease progression (approximately 2 years)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
ORR
Lasso di tempo: Part A: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years).

Percentage of participants with a confirmed CR or PR according to RECIST v1.1

Part A: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years).
Disease control rate (DCR)
Lasso di tempo: Part A, B, C, E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years). Part D: From randomization to PD or death in the absence of disease progression (approximately 2 years).

Percentage of participants who have a best objective response of confirmed CR or PR or who have SD lasting for at least a certain time of period after start of treatment

Part A, B, C, E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years). Part D: From randomization to PD or death in the absence of disease progression (approximately 2 years).
Duration of response (DoR)
Lasso di tempo: Part A, B, C, D and E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years).

The time from first response according to RECIST v1.1 until progression or death in the absence of disease progression

Part A, B, C, D and E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years).
Durable response rate (DRR)
Lasso di tempo: Part A, B, C, D and E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years).

The percentage of participants according to RECIST v1.1 with a confirmed CR or PR lasting 6 months or more

Part A, B, C, D and E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years).
Progression-free survival (PFS)
Lasso di tempo: Part B, C, E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years). Part D: From randomization to PD or death in the absence of disease progression (approximately 2 years).

The time from first dose of study intervention until the date of objective disease progression or death in the absence of disease progression

Part B, C, E: From first dose of rilvegostomig to PD or death in the absence of disease progression (approximately 2 years). Part D: From randomization to PD or death in the absence of disease progression (approximately 2 years).
Measure the receptor occupancy (RO) of TIGIT and PD-1 on peripheral blood
Lasso di tempo: Part A, B: From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B.

Evaluation of the target engagement of rilvegostomig in peripheral blood

Part A, B: From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B.
PK of rilvegostomig: Maximum plasma concentration of the study drug (Cmax)
Lasso di tempo: From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.

Maximum observed plasma concentration of rilvegostomig

From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.
PK of rilvegostomig: Area under the concentration-time curve (AUC)
Lasso di tempo: From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.

Area under the plasma concentration-time curve

From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.
PK of rilvegostomig: Clearance
Lasso di tempo: From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.

A pharmacokinetic measurement of the volume of plasma from which the study intervention is completely removed per unit time.

From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.
PK of rilvegostomig: Terminal elimination half-life (t 1/2)
Lasso di tempo: From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.

Terminal elimination half life

From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.
Incidence of anti-drug antibodies (ADA) against rilvegostomig in serum
Lasso di tempo: From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.

Immunogenicity of rilvegostomig

From first dose of study intervention, at predefined intervals throughout the administration of rilvegostomig (approximately 2 years). The predefined intervals for Part A will be different from Part B, C, D and E.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

14 settembre 2021

Completamento primario (Stimato)

1 giugno 2028

Completamento dello studio (Stimato)

1 giugno 2028

Date di iscrizione allo studio

Primo inviato

16 luglio 2021

Primo inviato che soddisfa i criteri di controllo qualità

29 luglio 2021

Primo Inserito (Effettivo)

9 agosto 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

10 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • D7020C00001
  • 2021-000857-23 (Numero EudraCT)
  • 2023-508262-15-00 (Identificatore di registro: EU CT Number)
  • 2023 (Sovvenzione/contratto NIH degli Stati Uniti)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.

All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Periodo di condivisione IPD

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Criteri di accesso alla condivisione IPD

When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level datain an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access.For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .